What is ERNAW's current stock price?

ERNAW (Ernexa Therapeutics Inc. Warrants) is currently trading at $0.14 with a market cap of $1.1M.

What sector is Ernexa Therapeutics Inc. Warrants in?

Ernexa Therapeutics Inc. Warrants (ERNAW) operates in the Financial Services sector, specifically in the Asset Management industry.

InvestLog

ERNAW Ernexa Therapeutics Inc. Warrants

Financial Services

$0.14-15.68%ClosedMarket Cap: $1.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

—

P/S

—

EV/EBITDA

—

DCF Value

—

FCF Yield

—

Div Yield

—

Margins & Returns

Gross Margin

—

Operating Margin

—

Net Margin

—

ROE

—

ROA

—

ROIC

—

Company Info

Sector

Financial Services

Industry

Asset Management

Country

Exchange

—

Beta

1.89

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.